Researchers in
the U.K. have evaluated additional findings about the immune-system impacts of
Lemtrada® (alemtuzimab, Sanofi Genzyme), a disease-modifying therapy for
treating people with relapsing MS.
The
team used data from phase 3 clinical trials submitted to the European Medicines
Agency during the drug’s successful approval process. Some of this data was
previously reported at medical meetings and in Lemtrada’s prescribing
information.
Among
their findings, they report that Lemtrada caused long-term reduction of
specific immune cells (memory B and T cells, including regulatory T cells).
They also found that the body rapidly repopulated an overabundance of immature
B cells.
They
propose that the blockade of memory B and T cells drives the beneficial effects
of Lemtrada.
They
also speculate that the known potential side effect for autoimmune thyroid
disease and other autoimmune disorders may be triggered by the overabundance of
immature B cells that occurs when there are few regulatory T cells to keep them
in check.
Studies
like this one, which reveal more information about a therapy’s mode of action,
are important and may also lead to insights about how to reduce side effects.
Drs.
Klaus Schmierer, David Baker and others at the Queen Mary University of London
report their findings in JAMA Neurology, published
online June 12, 2017.
Read the open-access paper in JAMA
Neurology
Read about Lemtrada
Read more about treating MS
Lemtrada is a registered trademark of Sanofi Genzyme
Read about Lemtrada
Read more about treating MS
Lemtrada is a registered trademark of Sanofi Genzyme